nach oben

Erschienen in:

18.06.2022 | COVID-19 | Original Paper

Carbapenem use correlates with percentage of patients with COVID-19 in intensive care units

verfasst von: Salma AlBahrani, Feras Almogbel, Wafa Alanazi, Saleh Hamdi Almutairi, Mohammed Alanazi, Sameh Maximos, Faten Azaiez, Assim Osman, Sharifah Almuthen, Arulanantham Zechariah Jebakumar, Jaffar A. Al-Tawfiq

Erschienen in: Infection | Ausgabe 2/2023

Einloggen, um Zugang zu erhalten

Abstract

Background

The first wave of COVID-19 pandemic may have significantly impacted antimicrobial consumption in hospitals. The objective of this study was to assess the evolution of carbapenem consumption and describe the implemented measures during the first year of the COVID-19 pandemic.

Methods

We calculated carbapenem consumption for all the hospital and for intensive care units (ICU) for three periods: baseline (before COVID-19 cases, January 2019–February 2020), and the period of COVID-19 cases as a pre-intervention (March–August 2020) and a post-intervention phase (September 2020–December 2021).

Results

During the study period, the percentage of admitted COVID-19 patients increased in the months of April–August of 2020 (pre-intervention period) from 5 to 26% of total admitted patients. The consumption of carbapenems (DDD/1000 patient days) increased from a mean of 67.1 at baseline to 142.9 pre-intervention. In ICUS, there was an increase in the mean from 125.7 to 240.8 DDD/1000 patient days. After interventions, the DDD/1000 patient days decreased by 49.5% overall the hospital and by 36% in ICUs. For the post-intervention period, there was a correlation between COVID-19 cases and carbapenem usage in the ICU but not the overall hospital.

Conclusion

An increase in the antimicrobial consumption during the first wave of COVID-19 pandemic was noticed, especially in the ICU. Antimicrobial stewardship programs are essential to reduce consumption rate.

Youngs J, Wyncoll D, Hopkins P, Arnold A, Ball J, Bicanic T. Improving antibiotic stewardship in COVID-19: bacterial co-infection is less common than with influenza. J Infect. 2020;81:e55–7. https://doi.org/10.1016/j.jinf.2020.06.056.CrossRefPubMedPubMedCentral

Lansbury L, Lim B, Baskaran V, Lim WS. Co-infections in people with COVID-19: a systematic review and meta-analysis. J Infect. 2020;81:266–75. https://doi.org/10.1016/j.jinf.2020.05.046.CrossRefPubMedPubMedCentral

Alhumaid S, Al Mutair A, Al Alawi Z, Alshawi AM, Alomran SA, Almuhanna MS, et al. Coinfections with bacteria, fungi, and respiratory viruses in patients with sars-cov-2: a systematic review and meta-analysis. Pathogens. 2021. https://doi.org/10.3390/pathogens10070809.CrossRefPubMedPubMedCentral

Zhu NJ, McLeod M, McNulty CAM, Lecky DM, Holmes AH, Ahmad R. Trends in antibiotic prescribing in out-of-hours primary care in england from January 2016 to June 2020 to understand behaviours during the firstwave of COVID-19. Antibiotics. 2021;10:1–10. https://doi.org/10.3390/antibiotics10010032.CrossRef

Guisado-Gil AB, Infante-Domínguez C, Peñalva G, Praena J, Roca C, Navarro-Amuedo MD, et al. Impact of the COVID-19 pandemic on antimicrobial consumption and hospital-acquired candidemia and multidrug-resistant bloodstream infections. Antibiot (Basel, Switzerland). 2020;9:1–11. https://doi.org/10.3390/ANTIBIOTICS9110816.CrossRef

Rothe K, Feihl S, Schneider J, Wallnöfer F, Wurst M, Lukas M, et al. Rates of bacterial co-infections and antimicrobial use in COVID-19 patients: a retrospective cohort study in light of antibiotic stewardship. Eur J Clin Microbiol Infect Dis. 2021;40:859–69. https://doi.org/10.1007/s10096-020-04063-8.CrossRefPubMed

Karami Z, Knoop BT, Dofferhoff ASM, Blaauw MJT, Janssen NA, van Apeldoorn M, et al. Few bacterial co-infections but frequent empiric antibiotic use in the early phase of hospitalized patients with COVID-19: results from a multicentre retrospective cohort study in The Netherlands. Infect Dis (Auckl). 2021;53:102–10. https://doi.org/10.1080/23744235.2020.1839672.CrossRef

Hsu J. How covid-19 is accelerating the threat of antimicrobial resistance. BMJ. 2020. https://doi.org/10.1136/bmj.m1983.CrossRefPubMed

Ginsburg AS, Klugman KP. COVID-19 pneumonia and the appropriate use of antibiotics. Lancet Glob Heal. 2020;8:e1453–4. https://doi.org/10.1016/S2214-109X(20)30444-7.CrossRef

10.

Al-Tawfiq JA. Changes in the pattern of hospital intravenous antimicrobial use in Saudi Arabia, 2006–2008. Ann Saudi Med. 2012;32:517–20.CrossRefPubMedPubMedCentral

11.

Al-Tawfiq JA, Al-Homoud AH. Pattern of systemic antibiotic use among hospitalized patients in a general hospital in Saudi Arabia. Travel Med Infect Dis. 2020. https://doi.org/10.1016/j.tmaid.2020.101605.CrossRefPubMedPubMedCentral

12.

AlJishi JM, Alhajjaj AH, Alkhabbaz FL, AlAbduljabar TH, Alsaif A, Alsaif H, et al. Clinical characteristics of asymptomatic and symptomatic COVID-19 patients in the Eastern Province of Saudi Arabia. J Infect Public Health. 2021;14:6–11. https://doi.org/10.1016/j.jiph.2020.11.002.CrossRefPubMed

13.

AlBahrani S, Al-Tawfiq JA, Jebakumar AZ, Alghamdi M, Zakary N, Seria M, et al. Clinical features and outcome of low and high corticosteroids in admitted COVID-19 patients. J Epidemiol Glob Health. 2021;11:316–9. https://doi.org/10.2991/jegh.k.210521.001.CrossRefPubMedPubMedCentral

14.

Barry M, Alotaibi M, Almohaya A, Aldrees A, AlHijji A, Althabit N, et al. Factors associated with poor outcomes among hospitalized patients with COVID-19: experience from a MERS-CoV referral hospital. J Infect Public Health. 2021;14:1658–65. https://doi.org/10.1016/j.jiph.2021.09.023.CrossRefPubMedPubMedCentral

15.

Castro-Lopes A, Correia S, Leal C, Resende I, Soares P, Azevedo A, et al. Increase of antimicrobial consumption in a tertiary care hospital during the first phase of the covid-19 pandemic. Antibiotics. 2021. https://doi.org/10.3390/antibiotics10070778.CrossRefPubMedPubMedCentral

16.

Al-Azzam S, Mhaidat NM, Banat HA, Alfaour M, Ahmad DS, Muller A, et al. An assessment of the impact of coronavirus disease (Covid-19) pandemic on national antimicrobial consumption in jordan. Antibiotics. 2021. https://doi.org/10.3390/antibiotics10060690.CrossRefPubMedPubMedCentral

17.

Rezel-Potts E, L’Esperance V, Gulliford MC. Antimicrobial stewardship in the UK during the COVID-19 pandemic: a population-based cohort study and interrupted time-series analysis. Br J Gen Pract. 2021;71:E331–8. https://doi.org/10.3399/BJGP.2020.1051.CrossRefPubMedPubMedCentral

18.

Zhu N, Aylin P, Rawson T, Gilchrist M, Majeed A, Holmes A. Investigating the impact of COVID-19 on primary care antibiotic prescribing in North West London across two epidemic waves. Clin Microbiol Infect. 2021;27:762–8. https://doi.org/10.1016/j.cmi.2021.02.007.CrossRefPubMedPubMedCentral

19.

Khan S, Hasan SS, Bond SE, Conway BR, Aldayeb MA. Antimicrobial consumption in patients with COVID-19: a systematic review and meta-analysis. Expert Rev Anti Infect Ther. 2021. https://doi.org/10.1080/14787210.2022.2011719.CrossRefPubMed

20.

Langford BJ, So M, Raybardhan S, Leung V, Soucy JPR, Westwood D, et al. Antibiotic prescribing in patients with COVID-19: rapid review and meta-analysis. Clin Microbiol Infect. 2021;27:520–31. https://doi.org/10.1016/j.cmi.2020.12.018.CrossRefPubMedPubMedCentral

21.

Langford BJ, So M, Raybardhan S, Leung V, Westwood D, MacFadden DR, et al. Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis. Clin Microbiol Infect. 2020;26:1622–9. https://doi.org/10.1016/j.cmi.2020.07.016.CrossRefPubMedPubMedCentral

22.

Garcia-Vidal C, Sanjuan G, Moreno-García E, Puerta-Alcalde P, Garcia-Pouton N, Chumbita M, et al. Incidence of co-infections and superinfections in hospitalized patients with COVID-19: a retrospective cohort study. Clin Microbiol Infect. 2021;27:83–8. https://doi.org/10.1016/j.cmi.2020.07.041.CrossRefPubMed

23.

Beovic B, Dousak M, Ferreira-Coimbra J, Nadrah K, Rubulotta F, Belliato M, et al. Antibiotic use in patients with COVID-19: A “snapshot” Infectious Diseases International Research Initiative (ID-IRI) survey. J Antimicrob Chemother. 2020;75:3386–90. https://doi.org/10.1093/jac/dkaa326.CrossRefPubMed

24.

Grau S, Echeverria-Esnal D, Gómez-Zorrilla S, Navarrete-Rouco ME, Masclans JR, Espona M, et al. Evolution of antimicrobial consumption during the first wave of covid-19 pandemic. Antibiotics. 2021;10:1–10. https://doi.org/10.3390/antibiotics10020132.CrossRef

25.

Silva ARO, Salgado DR, Lopes LPN, Castanheira D, Emmerick ICM, Lima EC. Increased use of antibiotics in the intensive care unit during coronavirus disease (COVID-19) pandemic in a Brazilian hospital. Front Pharmacol. 2021. https://doi.org/10.3389/fphar.2021.778386.CrossRefPubMedPubMedCentral

26.

da Silva RMR, de Mendonça SCB, Leão IN, dos Santos QN, Batista AM, Melo MS, et al. Use of monitoring indicators in hospital management of antimicrobials. BMC Infect Dis. 2021. https://doi.org/10.1186/s12879-021-06542-5.CrossRefPubMedPubMedCentral

27.

Yang Y, Geng X, Liu X, Wen X, Wu R, Cui D, et al. Antibiotic use in China’s public healthcare institutions during the COVID-19 pandemic: an analysis of nationwide procurement data, 2018–2020. Front Pharmacol. 2022. https://doi.org/10.3389/fphar.2022.813213.CrossRefPubMedPubMedCentral

28.

Khouja T, Mitsantisuk K, Tadrous M, Suda KJ. Global consumption of antimicrobials: impact of the WHO Global Action Plan on Antimicrobial Resistance and 2019 coronavirus pandemic (COVID-19). J Antimicrob Chemother. 2022. https://doi.org/10.1093/jac/dkac028.CrossRefPubMed

29.

Chan XHS, O’Connor CJ, Martyn E, Clegg AJ, Choy BJK, Soares AL, et al. Comparison of antibiotic use between the first two waves of COVID-19 in an Intensive Care Unit at a London Tertiary Centre: reducing broad-spectrum antimicrobial use did not adversely affect mortality. J Hosp Infect. 2022. https://doi.org/10.1016/j.jhin.2022.03.007.CrossRefPubMedPubMedCentral

30.

Al-Tawfiq JA, Al-Homoud AH. Intermittent daily de-escalation rounds did not have significant impact on antimicrobial stewardship program targeting carbapenems. Int J Clin Pract. 2021. https://doi.org/10.1111/ijcp.14507.CrossRefPubMed

31.

Khor WP, Olaoye O, D’arcy N, Krockow EM, Elshenawy RA, Rutter V, et al. The need for ongoing antimicrobial stewardship during the COVID-19 pandemic and actionable recommendations. Antibiotics. 2020;9:1–12. https://doi.org/10.3390/antibiotics9120904.CrossRef

32.

Pierce J, Stevens MP. COVID-19 and antimicrobial stewardship: lessons learned, best practices, and future implications. Int J Infect Dis. 2021;113:103–8. https://doi.org/10.1016/j.ijid.2021.10.001.CrossRefPubMedPubMedCentral

33.

Pulia MS, Wolf I, Schwei RJ, Chen D, Lepak AJ, Schulz LT, et al. Antibiotic prescribing patterns for coronavirus disease 2019 (COVID-19) in two emergency departments with rapid procalcitonin. Infect Control Hosp Epidemiol. 2021;42:359–61. https://doi.org/10.1017/ice.2020.1329.CrossRefPubMed

Titel: Carbapenem use correlates with percentage of patients with COVID-19 in intensive care units
verfasst von: Salma AlBahrani
Feras Almogbel
Wafa Alanazi
Saleh Hamdi Almutairi
Mohammed Alanazi
Sameh Maximos
Faten Azaiez
Assim Osman
Sharifah Almuthen
Arulanantham Zechariah Jebakumar
Jaffar A. Al-Tawfiq
Publikationsdatum: 18.06.2022
Verlag: Springer Berlin Heidelberg
Schlagwort: COVID-19
Erschienen in: Infection / Ausgabe 2/2023
Print ISSN: 0300-8126
Elektronische ISSN: 1439-0973
DOI: https://doi.org/10.1007/s15010-022-01867-y

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Frühzeitige HbA1c-Kontrolle macht sich lebenslang bemerkbar

22.05.2024 Typ-2-Diabetes Nachrichten

Menschen mit Typ-2-Diabetes von Anfang an intensiv BZ-senkend zu behandeln, wirkt sich positiv auf Komplikationen und Mortalität aus – und das offenbar lebenslang, wie eine weitere Nachfolgeuntersuchung der UKPD-Studie nahelegt.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Background

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2023

The role of pets in SARS-CoV-2 transmission: an exploratory analysis

Monkeypox in-patients with severe anal pain

A case of fulminant respiratory diphtheria in a 24-year-old Afghan refugee in Austria in May 2022: a case report

Diagnostic nomogram to differentiate between epididymal tuberculosis and bacterial epididymitis

Antibody responses and correlates after two and three doses of BNT162b2 COVID-19 vaccine